140 related articles for article (PubMed ID: 9215615)
1. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
2. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis.
Orlandi L; Colella G; Bearzatto A; Abolafio G; Manzotti C; Daidone MG; Zaffaroni N
Eur J Cancer; 2001 Mar; 37(5):649-59. PubMed ID: 11290441
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic reversal of drug resistance in ovarian cancer.
Ozols RF
Semin Oncol; 1985 Sep; 12(3 Suppl 4):7-11. PubMed ID: 4048979
[TBL] [Abstract][Full Text] [Related]
6. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
8. Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid.
Caffrey PB; Zhu M; Zhang Y; Chinen N; Frenkel GD
Cancer Lett; 1999 Feb; 136(1):47-52. PubMed ID: 10211938
[TBL] [Abstract][Full Text] [Related]
9. Modulation of melphalan cytotoxic activity in human melanoma cell lines.
Supino R; Caserini C; Orlandi L; Zaffaroni N; Silvestrini R; Vaglini M; Zunino F
Anticancer Drugs; 1996 Jul; 7(5):604-12. PubMed ID: 8862730
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
11. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
12. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents.
Yen L; Woo A; Christopoulopoulos G; Batist G; Panasci L; Roy R; Mitra S; Alaoui-Jamali MA
Mutat Res; 1995 Nov; 337(3):179-89. PubMed ID: 7491121
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Strumberg D; Harstrick A; Doll K; Hoffmann B; Seeber S
Anticancer Drugs; 1996 Jun; 7(4):415-21. PubMed ID: 8826610
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.
Bigioni M; Salvatore C; Palma C; Manzini S; Animati F; Lombardi P; Pratesi G; Supino R; Zunino F
Anticancer Drugs; 1997 Oct; 8(9):845-52. PubMed ID: 9402311
[TBL] [Abstract][Full Text] [Related]
18. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function.
Pu QQ; Bezwoda WR
Mol Pharmacol; 1999 Jul; 56(1):147-53. PubMed ID: 10385695
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
20. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]